Product Description
Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve symptoms of arthritis (osteoarthritis and rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure arthritis and will help you only as long as you continue to take it. (Sourced from: https://www.mayoclinic.org/drugs-supplements/flurbiprofen-oral-route/precautions/drg-20069793?p=1)
Mechanisms of Action: COX1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Transdermal,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Jiudian Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: Australia, China, Japan
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Osteoarthritis, Knee|Other|Pain, Postoperative
Phase 1: Agammaglobulinemia|Communicable Diseases|Healthy Volunteers|Inflammation|Osteoarthritis|Respiratory Tract Infections|Shoulder Pain|Tennis Elbow|Tenosynovitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2031240583 | P1 |
Not yet recruiting |
Inflammation |
2025-05-31 |
|
NCT05955885 | P1 |
Completed |
Communicable Diseases|Respiratory Tract Infections |
2024-07-01 |
|
jRCT2031230393 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-03-31 |
|
2006-7041-83/hah | P1 |
Not yet recruiting |
Agammaglobulinemia |
2018-03-18 |